A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
Clinical trial NCT03493854 · COMPLETED
Trial details
- NCT number
- NCT03493854
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-14
- Primary completion
- 2019-07-04
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.